These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24493578)

  • 21. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
    Locatelli F; Del Vecchio L
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.
    Arantes LH; Crawford J; Gascon P; Latymer M; Launay-Vacher V; Rolland C; Scotte F; Wish J
    Crit Rev Oncol Hematol; 2018 Sep; 129():79-90. PubMed ID: 30097240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
    Minutolo R; Bolasco P; Chiodini P; Sposini S; Borzumati M; Abaterusso C; Mele AA; Santoro D; Canale V; Santoboni A; Filiberti O; Fiorini F; Mura C; Imperiali P; Borrelli S; Russo L; De Nicola L; Russo D
    Clin Drug Investig; 2017 Oct; 37(10):965-973. PubMed ID: 28779268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study.
    Stoppa G; D'Amore C; Conforti A; Traversa G; Venegoni M; Taglialatela M; Leone R;
    BioDrugs; 2018 Aug; 32(4):367-375. PubMed ID: 30030767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.
    Di Iorio BR; Di Micco L; Russo L; Nardone L; De Simone E; Sirico ML; Di Natale G; Russo D
    G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An expert opinion on the current treatment of anemia in patients with kidney disease.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2012 Mar; 13(4):495-503. PubMed ID: 22296648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Lafeuille MH; Bailey RA; Vekeman F; Scott McKenzie R; Lefebvre P
    J Med Econ; 2012; 15(2):352-60. PubMed ID: 22168787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
    Spinowitz B; Pecoits-Filho R; Winkelmayer WC; Pergola PE; Rochette S; Thompson-Leduc P; Lefebvre P; Shafai G; Bozas A; Sanon M; Krasa HB
    J Med Econ; 2019 Jun; 22(6):593-604. PubMed ID: 30813807
    [No Abstract]   [Full Text] [Related]  

  • 30. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
    Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
    Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic considerations in a changing anemia environment.
    Pizzi LT
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S29-33. PubMed ID: 19010259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginesatide in patients with anemia undergoing hemodialysis.
    Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
    N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilar ESAs: a comparative review.
    Wilson P; Wood C
    J Ren Care; 2015 Mar; 41(1):53-61. PubMed ID: 25348203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
    Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
    J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.